Cellectis S A (CLLS) Return on Equity ROE from the fourth quarter 2025 to fourth quarter 2024 and annually, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Cellectis S a   (NASDAQ: CLLS)

Cellectis S A 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Cellectis S A in the fourth quarter 2025?
Cellectis S A recorded a cumulative net loss of $-91 million during 12 months ending in the fourth quarter 2025, resulting in a negative return on equity (ROE) of -112.47%.

Within the Biotechnology & Pharmaceuticals industry 80 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2025 from 0 to 3913.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Equity Change -42.07 % -42.07 % -34.65 % -42.07 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -91 -60 -60 -62 -62
Return On Equity (TTM) -112.47 % -63.69 % -55.62 % -50.99 % -45.8 %
CLLS's Total Ranking # 3913 # 0 # # #
Equity (TTM) in Millions 76 76 97 76 131
Seq. Equity Change 0 % -21.84 % 27.94 % -42.07 % 0 %
Seq. Net Income Change - - - - -

Back to CLLS Management Effectiveness >> CLLS's 5 Years Annual ROE >> Compare CLLS ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 81
Sector # 581
Overall # 3913

Return On Equity Statistics
High Average Low
-19.62 %
-45.02 %
-90.55 %
(Dec 31 2018)   (Dec 31 2022)





CLLS Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 76 131 85 126 236
Y / Y Equity Change -42.07 % 54.71 % -32.75 % -46.74 % -23.43 %
Net Income in Millions -68 -37 -108 -114 -125
Y / Y Net Income Change - - - - -
Return On Equity -89.05 % -28.05 % -128.04 % -90.55 % -52.91 %

Back to CLLS Management Effectiveness >> CLLS's 5 Years Annual ROE >> Compare CLLS ROE to its Competitors




More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
CLLS's' Return on Equity at Yahoo Finance
CLLS's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for CLLS's Competitors
Subscribers only: Roe for Cellectis S A 's Suppliers
Subscribers only: Return On Equity for CLLS's Customers




Companies with similar Return On Equity at Dec 31 2025, within Healthcare Sector ROE

Date modified: 2026-07-07T15:09:00+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.